Evaluacion de la capacidad inmunogénica de la vacuna antirrábica tipo Fuenzalida- Palacios (CRL) y de la vacuna antirrábica de cultivo celular (Verorab®) en personas con tratamiento preexposición

• Myriam Favi C ^[2] ; Verónica Yung P ^[2] ; Orietta Roos K ^[2] ; Luis Rodríguez A ^[2] ; Rodrigo Trujillo M ^[1] ; Attia Acevedo A ^[1]
  1. [1] Universidad Santo Tomás

     Universidad Santo Tomás

     Santiago, Chile

     
  2. [2] Instituto de Salud Pública
• Localización: Revista Médica de Chile, ISSN-e 0034-9887, Vol. 132, Nº. 1, 2004, págs. 41-46
• Idioma: español
• Títulos paralelos:
  • Immune response of suckling mouse brain (CRL) rabies vaccine and tissue culture rabies vaccine (Verorab®) in pre-exposure prophylaxis in humans
• Enlaces
  • Texto completo
• Resumen

  • A WHO experts committee recommended the substitution of antirabic vaccines produced in nervous tissue, by vaccines produced in tissue cultures. Aim: To compare the immunogenic capacity of antirabic vaccines CRL (produced in nervous tissue) and Verorab® (produced in tissue culture), used for pre-exposure prophylaxis in humans. Patients and methods: Fifty four volunteers were immunized for this study. The first group, vaccinated with CLR was treated with a scheme of 4 subcutaneous peri umbilical doses in days 0, 3, 7 and 28. The second group, vaccinated with Verorab® vaccine was treated with a scheme of 3 intramuscular doses in deltoid zone at days 0, 7 and 28. Blood samples were obtained at days 0, 7, 42 and 365 to measure neutralizing antibodies using the Inhibition of Fluorescent Focus Technique (RFFIT). Results: At day seven, a primary non protective immunologic response was observed in both groups, with titers significantly higher in the group vaccinated with Verorab®. At day 42, no differences were observed. At day 365, all subjects vaccinated with Verorab® and 50% of individuals vaccinated with CRL had protective antibody titers (p <0,05). Conclusions: The vaccine produced in cell breeds (Verorab®) produces a better an faster immunologic response compared to the CRL vaccine (Rev Méd Chile 2004; 132: 41-6).